Name of organisation
1) Department/Research groupOXON Epidemiology
2) Organisation/affiliationOXON Epidemiology Ltd.
Short Name in the inventoryOXON
Administrative Contact
Title Professor
Last name Qizilbash MBChB MRCP(UK) MSc DPhil(Oxon)
First name Nawab
Address line 1The Euston Office
Address line 21 Euston Square
Address line 340 Melton Street
CityLondon
PostcodeNW1 2FD
CountryUnited Kingdom
Phone number (incl. country code)34-913459395
Alternative phone number44-7749730566
Fax number (incl. country code)34-913459394
Scientific Contact
Title Professor
Last name Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.)
First name Nawab
Address line 1Calle Dr. Fleming 51
Address line 2
Address line 3
CityMadrid
Postcode28036
CountrySpain
Phone number (incl. country code)34-913459395
Alternative phone number34-629846059
Fax number (incl. country code)34-913459394
Alternative Scientific Contact
Title Professor
Last name Rennie MA (Cantab) MSc PhD
First name Kirsten
Address line 1The Euston Office
Address line 21 Euston Square
Address line 340 Melton Street
CityLondon
PostcodeNW1 2FD
CountryUnited Kingdom
Phone number (incl. country code)442035744617
Alternative phone number447887850794
Fax number (incl. country code)442033977497
2. Description
OXON Epidemiology is a full-service global scientific service provider specialising in global safety and outcomes field & database observational studies.
• Prospective/registry studies
• Cross-sectional studies
• Risk minimisation surveys
• Retrospective chart review studies
• Database studies
• Hybrid studies
With a staff that are co-authors of (x7) Lancet, (x1) JAMA and (x3) BMJ articles; strong links with leading EU academic database epidemiologists; and a long-term alliance with a top tier CRO, OXON competes on a global scale providing a unique blend of observational science and operational excellence to help clients worldwide obtain high quality real-world data for improving patients and public health in major therapeutic areas, particularly.
• Oncology / Haematology
• Cardiovascular disease
• Metabolic / Diabetes / Bone
• Gastroenterology
• Immunology
• Vaccines / Infectious diseases
• Neuroscience
• Paediatrics
• Respiratory disease
• Orphan conditions
• Urology / Renal
3. Category
For profit organisation
Clinical and academic affiliations
4. Available resources
In houseVia Contacts/Network
Epidemiologist/Pharmacoepidemiologist
Yes
Yes
Statistician
Yes
Yes
Clinician
Yes
Yes
Clinical Pharmacologist
No
Yes
Pharmacist
Yes
Yes
Geneticist/Pharmacogeneticist
No
Yes
IT specialist
Yes
Yes
Ethics expertise
No
Yes
Legal expertise
No
Yes
Regulatory expertise
Yes
Yes
Safety expertise
Yes
Yes
Patient reported outcomes expertise
Yes
Yes
Health economics expertise
Yes
Yes
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Devices
Disorders of the central nervous system
Endocrine disorders
Eye disorders
Gastrointestinal tract
Geriatrics
Gynaecology
Immunological products and vaccines
Infectious diseases
Malignant disease
Musculoskeletal and joint diseases
Nutrition and blood
Osteoporosis
Paediatrics
Psychiatry
Renal impairment
Respiratory diseases
Skin disorders
Urinary tract disorders
Pain
Orphan diseases
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Meta-Analysis
Benefit-risk analysis
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Less than 150
Between 150 and 1499
Between 1500 and 14999
Greater than 15000
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
Proprietary web-based capture system
Interactive voice response systems
Yes
Call centre
Yes
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
CPRD13
THIN17
IHCIS0
IMS Lifelink1
AERS / Vigibase19
11. Registries established by centre
Drug RegistryParkinson´s disease
Disease RegistryGastroenterology, schizophrenia, heart failure
Other Multi-country observational studies with clinical, safety, PRO, health care resource, drug utilisation and HE outcomes
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
None